Logo image of ONC

BEONE MEDICINES LTD-ADR (ONC) Stock Overview

USA - NASDAQ:ONC - US07725L1026 - ADR

326.06 USD
-2.65 (-0.81%)
Last: 9/26/2025, 8:20:48 PM
326.06 USD
0 (0%)
After Hours: 9/26/2025, 8:20:48 PM

ONC Key Statistics, Chart & Performance

Key Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap38.76B
Shares118.88M
Float8.51M
Yearly Dividend0.51
Dividend YieldN/A
EPS(TTM)57.19
PE5.7
Fwd PE66.31
Earnings (Next)11-12 2025-11-12
IPO02-03 2016-02-03
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ONC short term performance overview.The bars show the price performance of ONC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30

ONC long term performance overview.The bars show the price performance of ONC in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of ONC is 326.06 USD. In the past month the price increased by 9.43%.

BEONE MEDICINES LTD-ADR / ONC Daily stock chart

ONC Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.83 389.72B
AMGN AMGEN INC 12.52 146.96B
GILD GILEAD SCIENCES INC 14.48 139.09B
VRTX VERTEX PHARMACEUTICALS INC 22.77 98.90B
REGN REGENERON PHARMACEUTICALS 12.36 59.77B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.51B
ARGX ARGENX SE - ADR 76.77 43.55B
INSM INSMED INC N/A 28.96B
BNTX BIONTECH SE-ADR N/A 23.58B
NTRA NATERA INC N/A 22.37B
BIIB BIOGEN INC 8.58 20.14B
UTHR UNITED THERAPEUTICS CORP 16.89 19.57B

About ONC

Company Profile

ONC logo image BeOne Medicines AG is a CH-based company operating in Biotechnology industry. The company is headquartered in Basel, Basel-Stadt and currently employs 11,075 full-time employees. BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. The company is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.

Company Info

BEONE MEDICINES LTD-ADR

c/o BeOne Medicines I GmbH, Aeschengraben 27, 21st Floor

Basel BASEL-STADT CH

Employees: 11075

Phone: 41616851900

BEONE MEDICINES LTD-ADR / ONC FAQ

What is the stock price of BEONE MEDICINES LTD-ADR today?

The current stock price of ONC is 326.06 USD. The price decreased by -0.81% in the last trading session.


What is the ticker symbol for BEONE MEDICINES LTD-ADR stock?

The exchange symbol of BEONE MEDICINES LTD-ADR is ONC and it is listed on the Nasdaq exchange.


On which exchange is ONC stock listed?

ONC stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for BEONE MEDICINES LTD-ADR stock?

14 analysts have analysed ONC and the average price target is 344.56 USD. This implies a price increase of 5.67% is expected in the next year compared to the current price of 326.06. Check the BEONE MEDICINES LTD-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BEONE MEDICINES LTD-ADR worth?

BEONE MEDICINES LTD-ADR (ONC) has a market capitalization of 38.76B USD. This makes ONC a Large Cap stock.


How many employees does BEONE MEDICINES LTD-ADR have?

BEONE MEDICINES LTD-ADR (ONC) currently has 11075 employees.


What are the support and resistance levels for BEONE MEDICINES LTD-ADR (ONC) stock?

BEONE MEDICINES LTD-ADR (ONC) has a support level at 314.39 and a resistance level at 327.94. Check the full technical report for a detailed analysis of ONC support and resistance levels.


Is BEONE MEDICINES LTD-ADR (ONC) expected to grow?

The Revenue of BEONE MEDICINES LTD-ADR (ONC) is expected to grow by 41.54% in the next year. Check the estimates tab for more information on the ONC EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BEONE MEDICINES LTD-ADR (ONC) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BEONE MEDICINES LTD-ADR (ONC) stock pay dividends?

ONC does not pay a dividend.


When does BEONE MEDICINES LTD-ADR (ONC) report earnings?

BEONE MEDICINES LTD-ADR (ONC) will report earnings on 2025-11-12.


What is the Price/Earnings (PE) ratio of BEONE MEDICINES LTD-ADR (ONC)?

The PE ratio for BEONE MEDICINES LTD-ADR (ONC) is 5.7. This is based on the reported non-GAAP earnings per share of 57.19 and the current share price of 326.06 USD. Check the full fundamental report for a full analysis of the valuation metrics for ONC.


What is the Short Interest ratio of BEONE MEDICINES LTD-ADR (ONC) stock?

The outstanding short interest for BEONE MEDICINES LTD-ADR (ONC) is 17.48% of its float. Check the ownership tab for more information on the ONC short interest.


ONC Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to ONC.


Chartmill TA Rating
Chartmill Setup Rating

ONC Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to ONC. ONC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ONC Financial Highlights

Over the last trailing twelve months ONC reported a non-GAAP Earnings per Share(EPS) of 57.19. The EPS increased by 217.74% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -3.68%
ROE -6.15%
Debt/Equity 0.26
Chartmill High Growth Momentum
EPS Q2Q%104.68%
Sales Q2Q%40.76%
EPS 1Y (TTM)217.74%
Revenue 1Y (TTM)47.67%

ONC Forecast & Estimates

14 analysts have analysed ONC and the average price target is 344.56 USD. This implies a price increase of 5.67% is expected in the next year compared to the current price of 326.06.

For the next year, analysts expect an EPS growth of 121.46% and a revenue growth 41.54% for ONC


Analysts
Analysts81.43
Price Target344.56 (5.67%)
EPS Next Y121.46%
Revenue Next Year41.54%

ONC Ownership

Ownership
Inst Owners33.86%
Ins OwnersN/A
Short Float %17.48%
Short Ratio3.77